BRITTANY HICKS: Open Payments
NPI 1538431002 · GULFPORT, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,825 in 195 payments from 46 companies in 2025. Trend: 2023 $3,221 · 2024 $3,141 · 2025 $3,825
Food & beverage: $3,825
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 27 | $333 |
| Janssen Biotech, Inc. | 15 | $247 |
| Merck Sharp & Dohme LLC | 11 | $236 |
| PFIZER INC. | 11 | $218 |
| Exelixis Inc. | 18 | $194 |
| Daiichi Sankyo Inc. | 10 | $190 |
| E.R. Squibb & Sons, L.L.C. | 5 | $187 |
| Celgene Corporation | 7 | $146 |
| Incyte Corporation | 7 | $146 |
| TG Therapeutics, Inc. | 1 | $142 |
Products named: REBLOZYL, KEYTRUDA, CABOMETYX, KISQALI, IBRANCE, BRIUMVI, VERZENIO, Lenvima.
Industry payments across MS — which companies pay providers there.
